Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
11. |
ECCT/24/03/04 | MK8591A-053 Trial A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants |
Principal Investigator(s) 1. Elizabeth Anne Bukusi 2. Nelly Rwamba Mugo Site(s) in Kenya 1. Site 8650, KEMRI-CMR-RCTP, Kisumu (Kisumu county) 2. Site 8651, KEMRI-CCR-PHRD, Thika (Kiambu county) 3. Site 8652, KEMRI-CCR, NAIROBI (Nairobi City county) |
View |
12. |
ECCT/23/03/04 | CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) |
View |
13. |
ECCT/21/06/13 | CARES A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) 3. Aga khan University Hospital (Nairobi City county) |
View |
14. |
ECCT/22/11/03 | BFAST A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL) |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya Aga Khan University, Nairobi |
View |
15. |
ECCT/23/01/08 | SKY-06 A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya International Cancer Institute |
View |